Progenra is harnessing protein regulation to produce new medicines for various diseases.
Progenra, Inc. harnesses protein regulation to discover new medicines to treat cancer, cardiovascular and pulmonary disease, inflammation, cystic fibrosis, and other devastating illnesses representing unmet medical needs. Core competencies include molecular biology, protein biochemistry, cell biology and biochemistry, assay development, high throughput screening, medicinal chemistry, pharmaceutical project and portfolio management, and preclinical drug development.
Interview Q&A
How long have you been in business?
20 Years
What is your primary product or service?
Progenra's mission is to leverage its expertise in the ubiquitin-proteasomal pathway and cellular protein regulation, acquired over several years, to discover and develop medicines to fill unmet medical needs in a spectrum of therapeutic areas.
How did you first become interested in your line of business? (if owner) - What is your background? (If owner or store manager)
Tauseef R Butt, Ph.D.
President and Chief Executive Officer
Dr. Butt has a PhD from the University of Glasgow, UK, and trained as a Postdoctoral Fellow at the Georgetown University School of Medicine and a Staff Fellow at the National Institutes of Health, Bethesda, MD, before joining SmithKline Beckman (now GSK) Pharmaceuticals in 1982. He worked in several therapeutic areas during his 14 years in the SmithKline organization, where he led one of the first ubiquitin drug discovery efforts in the industry. Dr. Butt has an appointment as Adjunct Professor in Biomedical Engineering at Drexel University, Philadelphia and is active in a number of national and regional biotechnology organizations. He is a co-founder of Progenra, Inc.
How do you differentiate yourself from other businesses in your category and area?
E3 ligases conjugate ubiquitin to specific target proteins, signaling changes such as directing them to the proteasome for degradation. DUBs cleave ubiquitin from target proteins, including other ubiquitins. Ubiquitin conjugation and deconjugation both have physiological consequences and can be manipulated by small molecules for therapeutic effect.
Since 2002 Progenra scientists have been working to understand the intricacies of the ubiquitin pathway to maximize discovery of new classes of molecules. This work has led to the creation of a comprehensive toolbox termed the UbiPro™ Drug Discovery Platform for studying DUBs and E3 Ligases which we use to screen our diverse collection of >200,000 drug-like small molecules.
How many locations do you have and do you have plans to expand?
1
Provide detailed directions to your location
A) Pennsylvania Turnpike to Phoenixville Exit 320. Turn Left onto N. Moorehall Road. Turn Right onto Great Valley Parkway. Turn Left at STOP Sign. Building on the Left.
B) If coming from West Chester Area take 202 North to the PA-29/Malvern/Great Valley Exit. Keep Left past, then keep right take the PA-29 N/Great Valley Exit. Turn right onto Matthews Road. Turn right onto Morehall Road/PA-29. Turn Left onto Great Valley Parkway. Turn left at STOP sign. Building on the LEFT.
C) If coming from Philadelphia/King of Prussia. Take I-76 W/Schuykill Expy West toward Valley Forge. Merge onto US-202 South via Exit 328B/A toward West Chester. Take the exit toward Great Valley/PA-29 N. Keep left to ramp toward Penn State Great Valley Campus/Immaculate Univ. Turn left onto E. Swedesford Road. Turn Right onto Morehall Rd/PA-29. Turn left onto Great Valley Pkwy. Turn Left at STOP sign. Building on the LEFT.
What type of payments do you accept?
New accept Purchase Orders and Credit Card Orders
Which areas do you service?
International
Who owns your company or runs daily operations?
Tauseef Butt, PhD
What are your hours of operation?
8 - 5pm
What is the best compliment anyone can give you?
That we are innovative and are a leader in our industry.
What is your favorite quote or Bible verse?
"If your actions inspire others to dream more, learn more, do more and become more, you are a leader."